---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-003318"
form_type: "8-K"
ticker: "PBSV"
cik: "0001304161"
company_name: "Pharma-Bio Serv, Inc."
filed_at: "2024-03-18T23:59:59+00:00"
generated_at: "2026-06-04T14:40:01.589445+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pharma-Bio Serv Q1 revenue down 44% to $2.4M; swings to net loss of $270.7K

## Summary
- Revenue for Q1 ended Jan 31, 2024: $2.4M, down $1.9M from $4.3M in prior-year quarter.
- Net loss of ~$270.7K vs net income of $426.4K in the same quarter last year.
- CEO cites planned investments in business development to drive future growth and profitability.
- No specific financial guidance or outlook provided for fiscal year 2024.

## SEC filing metadata
- accession: 0001654954-24-003318
- form_type: 8-K
- ticker: PBSV
- cik: 0001304161
- company_name: Pharma-Bio Serv, Inc.
- filed_at: 2024-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1304161/000165495424003318/0001654954-24-003318-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1304161/000165495424003318/pbsv_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-003318
- JSON: https://secwatch.observer/filing/0001654954-24-003318.json
- Plain text: https://secwatch.observer/filing/0001654954-24-003318.txt

## Key facts
- Earnings Releases
  Pharma-Bio Serv, Inc. reported the quarter ended January 31, 2024 results: revenue approximately $2.4 million, net income approximately $270,700.
  - Period: the quarter ended January 31, 2024
  - Revenue: approximately $2.4 million
  - Net income: approximately $270,700
  - Result: reported results
  source text: today announced that revenues for the quarter ended January 31, 2024 were approximately $2.4 million, a decrease of approximately $1.9 million when compared to the same period last year. Net loss for the quarter ended January 31, 2024 was approximately $270,700 compared to a net income of approximately $426,400 for the same period last year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1304161/000165495424003318/0001654954-24-003318-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.